Schizophrenia Clinical Trials in Nashville, Tennessee

4 studies are recruiting for schizophrenia in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

    Stage
    Phase 3
    Ages
    13 to 17
    Site
    Local Institution - 0113, Nashville, Tennessee
    Locations
    38 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07288567 on ClinicalTrials.gov

  2. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Access Clinical Trials, Nashville, Tennessee
    Locations
    64 in total
    Run by
    Intra-Cellular Therapies, Inc.

    See if you can join NCT06229210 on ClinicalTrials.gov

  3. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

    The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Local Institution - 0137, Nashville, Tennessee
    Locations
    91 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07424404 on ClinicalTrials.gov

  4. Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia

    The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitan…

    Stage
    Not phased
    Ages
    18 to 65
    Site
    Vanderbilt Psychiatric Hospital, Nashville, Tennessee
    Run by
    Vanderbilt University Medical Center

    See if you can join NCT07196462 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.